Patents Examined by Mark L. Berch
  • Patent number: 8236951
    Abstract: There is disclosed the use of a compound of formula (Ia) or (Ib) wherein R1, R2, R3, R4, X and Y are as defined in the specification, and pharmaceutically acceptable salts thereof, in the manufacture of a medicament, for the treatment or prophylaxis of diseases or conditions in which inhibition of the enzyme myeloperoxidase (MPO) is beneficial. Certain novel compounds of formula (Ia) or (Ib) and pharmaceutically acceptable salts thereof are disclosed, together with processes for their preparation. The compounds of formulae (Ia) and (Ib) are MPO inhibitors and are thereby particularly useful in the treatment or prophylaxis of neuroinflammatory disorders.
    Type: Grant
    Filed: August 4, 2008
    Date of Patent: August 7, 2012
    Assignee: AstraZeneca AB
    Inventors: Sverker Hanson, Gunnar Nordvall, Anna-Karin Tiden
  • Patent number: 8080551
    Abstract: HIV replication inhibitors having formula (I) defined herein are disclosed. Pharmaceutical compositions containing the HIV replication inhibitors; the use of the HIV replication inhibitors in the treatment of HIV; and processes for preparing the HIV replication inhibitors are also disclosed.
    Type: Grant
    Filed: June 26, 2006
    Date of Patent: December 20, 2011
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Jérôme Emile Georges Guillemont, Patrice Palandijian, Marc René De Jonge, Lucien Maria Henricus Koymans, Hendrik Maarten Vinkers, Frederik Frans Desiré Daeyaert, Jan Heeres, Koen Jeanne Alfons Van Aken, Paulus Joannes Lewi, Paul Adriaan Jan Janssen, Frank Xavier Jozef Herwig Arts, legal representative
  • Patent number: 8012964
    Abstract: The present invention provides an 8-oxoadenine compound having immunemodulating activities such as an interferon inducing activity and useful as an antiviral agent and antiallergic agent, which is represented by the following formula (1): [wherein the ring A represents a 6-10 membered aromatic carbocyclic ring and the like, R represents a halogen atom, an alkyl group and the like, n represents an integer of 0-2, Z1 represents alkylene, X2 represents oxygen atom, sulfur atom, SO2, NR5, CO, CONR5, NR5CO and the like, Y1, Y2 and Y3 represent independently a single bond or an alkylene group, X1 represents oxygen atom, sulfur atom, NR4 (R4 is hydrogen atom or an alkyl group) or a single bond, R2 represents a substituted or unsubstituted alkyl group, R1 represents hydrogen atom, hydroxy group, an alkoxy group, an alkoxycarbonyl group or a haloalkyl group] or its pharmaceutically acceptable salt.
    Type: Grant
    Filed: March 24, 2005
    Date of Patent: September 6, 2011
    Assignees: Dainippon Sumitomo Pharma Co., Ltd., Astrazeneca Aktiebolag
    Inventors: Ayumu Kurimoto, Yoshiaki Isobe, Stephen Brough, Hiroki Wada, Roger Bonnert, Thomas McInally
  • Patent number: 7985754
    Abstract: The present invention provides compounds of formulae Ia and Ib: wherein R1-5, Q, X, Y, Z, p, q, and r are as defined herein. The compounds are potent and selective antagonists of A2A adenosine receptors (ARs). The invention further includes pharmaceutical compositions containing these compounds and methods of using the same.
    Type: Grant
    Filed: July 16, 2007
    Date of Patent: July 26, 2011
    Assignee: Trovis Pharmaceuticals, LLC
    Inventors: Anthony Beauglehole, Jayson M. Rieger, Robert D. Thompson
  • Patent number: 7977475
    Abstract: The present invention is related to processes for the preparation of faropenem, which comprises treating the compound of Formula II, with an alkali metal salt of a substituted or unsubstituted C5-10 carboxylic acid and a catalytic amount of a palladium complex in the presence of an organic solvent, followed by the treatment of the reaction mixture of with water and a water miscible solvent, and isolating a hydrate of an alkali metal salt of faropenem from the reaction mass, wherein water is not removed from the reaction mixture in water treatment or isolation steps.
    Type: Grant
    Filed: October 5, 2006
    Date of Patent: July 12, 2011
    Assignee: Ranbaxy Laboratories Limited
    Inventors: Neela Praveen Kumar, Mohan Prasad
  • Patent number: 7977344
    Abstract: The present invention includes novel compounds useful in the treatment of various disorders in particular infectious diseases, cancer, and allergic diseases and other inflammatory conditions for example allergic rhinitis and asthma, and as vaccine adjuvants.
    Type: Grant
    Filed: February 15, 2008
    Date of Patent: July 12, 2011
    Assignee: GlaxoSmithKline LLC
    Inventors: Linos Lazarides, Stephen Allan Smith, Richard Stocker, Colin Jack Theobald
  • Patent number: 7968556
    Abstract: Provided herein are Heteroaryl Compounds having the following structure: wherein R1, R3, R4, L, X, Y, A and B are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, metabolic conditions and conditions treatable or preventable by inhibition of a kinase pathway comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.
    Type: Grant
    Filed: October 18, 2007
    Date of Patent: June 28, 2011
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Deborah Sue Mortensen, Maria Mercedes Delgado Mederos, John Joseph Sapienza, Ronald J. Albers, Steven Spencer Clareen, Kimberly Lyn Schwarz, Jason Simon Parnes, Jennifer R. Riggs, Patrick William Papa, Sayee Gajanan Hegde, Jeffrey Mark McKenna
  • Patent number: 7968544
    Abstract: The present application includes a compound of Formula I or II: or a pharmaceutically acceptable-salt, solvate, and/or ester thereof, compositions containing such compounds, therapeutic methods that include the administration of such compounds, and therapeutic methods that include the administration of such compounds with at least one additional active agent.
    Type: Grant
    Filed: June 26, 2008
    Date of Patent: June 28, 2011
    Assignee: Gilead Sciences, Inc.
    Inventors: Michael Graupe, Randall L. Halcomb
  • Patent number: 7951803
    Abstract: Compounds of the formula wherein R1 represents optionally substituted C1-C10 alkyl, aryl or heteroaryl, and R3 represents alkoxy-substituted aryl or optionally substituted heteroaryl, are disclosed as Mnk2 inhibitors which are useful for the treatment and prevention of metabolic disorders such as obesity and diabetes.
    Type: Grant
    Filed: March 9, 2007
    Date of Patent: May 31, 2011
    Assignee: Pharmacopeia, LLC
    Inventors: Andrew G. Cole, Marc-Raleigh Brescia, Joan J. Zhang, Zahid Hussain, David J. Diller, Axel Metzger, Gulzar Ahmed, Ian Henderson
  • Patent number: 7943625
    Abstract: The present invention relates to a compound according to Formula (I) wherein R1 is selected from C1-C6 alkyl, and said C1-C6 alkyl is substituted with C1-C6 alkoxy; and at least one of said C1-C6 alkyl or said C1-C6 alkoxy is branched; or a pharmaceutically acceptable salt thereof, solvate or solvate of a salt thereof, as well as, to compositions containing at least one compound according to Formula (I) and methods of treating at least one disease or condition therewith.
    Type: Grant
    Filed: June 1, 2007
    Date of Patent: May 17, 2011
    Assignee: AstraZeneca AB
    Inventor: Anna-Karin Tidén
  • Patent number: 7935818
    Abstract: A process for the preparation of valgancyclovir which comprises: a) reacting a compound of formula 7, in an aprotic solvent, in the presence of a condensing agent, with a compound of formula 8, wherein R1, and R2 may be, each independently, hydrogen, an halogen atom or an hydroxyl group; the double bond may either be in the E or Z configuration or a mixture thereof to yield a compound of formula 9 b) mild hydrolysis of compound obtained in a) to give valgancyclovir.
    Type: Grant
    Filed: June 20, 2007
    Date of Patent: May 3, 2011
    Assignee: Fidia Farmaceutici S.p.A.
    Inventors: Gianluca Belogi, Alessia Rossi, Angelo Bedeschi, Roberta Pizzocaro
  • Patent number: 7935817
    Abstract: Provided are a cocrystal of Adefovir dipivoxil and nicotinamide as well as a cocrystal of Adefovir dipivoxil and salicylamide cocrystal and processes for the preparation thereof.
    Type: Grant
    Filed: March 31, 2008
    Date of Patent: May 3, 2011
    Assignee: Apotex Pharmachem Inc.
    Inventors: Peter Garth Blazecka, Daqing Che, Cameron L. McPhail, Allan W. Rey
  • Patent number: 7932381
    Abstract: An object of the present invention is to provide a carbapenem synthetic intermediate which is advantageous in an industrial process. There are provided a process for producing Compound (I), or a pharmaceutically acceptable salt, or a solvate, or a crystal thereof, comprising reacting Compound (III) and Compound (IV) in the presence of the secondary amine, and a benzyl alcoholated crystal of Compound (I). There are further provided a method of deprotecting Compound (I) with a Pd catalyst, and a crystal of Compound (IV).
    Type: Grant
    Filed: February 14, 2006
    Date of Patent: April 26, 2011
    Assignee: Shionogi & Co., Ltd.
    Inventor: Yasuyuki Hozumi
  • Patent number: 7919490
    Abstract: The present invention provides novel purinones and purines useful for the prevention and treatment of autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection.
    Type: Grant
    Filed: October 4, 2007
    Date of Patent: April 5, 2011
    Assignee: Wyeth LLC
    Inventors: Irina Neagu, David Diller, Celia Kingsbury, Adolph C. Bohnstedt, Michael J. Ohlmeyer, Vidyadhar Paradkar, Nasrin Ansari
  • Patent number: 7919616
    Abstract: The present invention relates to a carbapenem compound represented by formula (Ia) shown below: The carbapenem compound preferably has a crystalline form, and more preferably, the crystalline form has a powder X-ray diffraction pattern with peaks at 15.64, 9.93, 6.83, 6.52, 5.44, 5.01, 4.72, 4.50, 4.33, 4.24, 3.98, 3.85, 3.57, 3.41, 3.31, 3.10 2.76, and 2.67 as d-spacings (?).
    Type: Grant
    Filed: October 31, 2006
    Date of Patent: April 5, 2011
    Assignee: Nippon Soda Co., Ltd.
    Inventor: Satoshi Kajita
  • Patent number: 7915268
    Abstract: The present invention provides novel purines useful for the prevention and treatment of autoimmune diseases, inflammatory diseases, mast cell mediated disease and transplant rejection.
    Type: Grant
    Filed: October 4, 2007
    Date of Patent: March 29, 2011
    Assignee: Wyeth LLC
    Inventors: Yingchun Lu, Celia Kingsbury, Adolph Bohnstedt, Michael Ohlmeyer, Vidyadhar Paradkar
  • Patent number: 7906502
    Abstract: Compounds of formula (I) (wherein variable groups are as defined within) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia are described. Processes for their manufacture and pharmaceutical compositions containing them are also described.
    Type: Grant
    Filed: June 21, 2006
    Date of Patent: March 15, 2011
    Assignee: AstraZeneca AB
    Inventors: Susanne Alenfalk, Mikael Dahlstrom, Fana Hunegnaw, Staffan Karlsson, Ingemar Starke
  • Patent number: 7906518
    Abstract: The invention relates to a method of improving oral drug absorption of adenosine analogues by the use of 2?,3?-methylidene acetal adenosine pro-drugs and to the use of these pro-drugs as medicaments. The invention further relates to compounds that are pro-drugs of adenosine receptor agonists, and to their use as therapeutic compounds, in particular as analgesic or anti-inflammatory compounds, or as disease modifying antirheumatic drugs (DMARDs), and to methods of preventing, treating or ameliorating pain or inflammation using these compounds.
    Type: Grant
    Filed: June 26, 2007
    Date of Patent: March 15, 2011
    Assignee: CBT Development Limited
    Inventor: Edward D. Savory
  • Patent number: 7902157
    Abstract: Disclosed are compounds of the formula wherein Z1 is —CH2—or —C(O)—, R4 and R5 are carbon chains (and optionally, together can form a C2 bridge), u and v are independently an integer of 0-3 such that there sum is from 3 to 5, and R2 is heteroaryl, and R1 and R3 are as defined herein. Also disclosed are methods of treating pain, and methods of inhibiting the absorption of cholesterol using a compound of formula I.
    Type: Grant
    Filed: September 13, 2007
    Date of Patent: March 8, 2011
    Assignee: Schering Corporation
    Inventors: Duane A. Burnett, Brian A. McKittrick
  • Patent number: RE42461
    Abstract: Hydroxy-substituted azetidinone hypocholesterolemic agents of the formula or a pharmaceutically acceptable salt thereof, wherein: Ar1 and Ar2 are aryl or R4-substituted aryl; Ar3 is aryl or R5-substituted aryl; X, Y and Z are —CH2—, —CH(lower alkyl)— or —C(dilower alkyl)—; R and R2 are —OR6, —O(CO)R6, —O(CO)OR9 or —O(CO)NR6R7; R1 and R3 are H or lower alkyl; q is 0 or 1; r is 0 or 1; m, n and p are 0-4; provided that at least one of q and r is 1, and the sum of m, n, p, q and r is 1-6; and provided that when p is O and r is 1, the sum of m, q and n is 1-5; R4 is selected from lower alkyl, R5, —CF3, —CN, —NO2 and halogen R5 is selected from —OR6, —O(CO)R6, —O(CO)OR9, —O(CH2)1-5OR6, —O(CO)NR6R7, —NR6R7, —NR6(CO)R7, —NR6(CO)OR9, —NR6(CO)NR7R8, —NR6SO2R9, —COOR6, —CONR6R7, —COR6, —SO2NR6R7, S(O)0-2R9, —O(CH2)1-10—COOR6, —O(CH2)1-10CON6R7, —(lower alkylene)COOR6 and —CH?CH—COOR6; R6, R7 and R8 are H, lower alkyl or aryl-substituted Ic R9 is lower alkyl, aryl or aryl-substituted lower alkyl; are discl
    Type: Grant
    Filed: September 14, 1994
    Date of Patent: June 14, 2011
    Assignee: Schering Corporation
    Inventors: Stuart B. Rosenblum, Sundeep Dugar, Duane A. Burnett, John W. Clader, Brian A. McKittrick